BioSyent Pharma Launches Cathejell(TM) Jelly 2%; S

BioSyent Pharma Launches Cathejell(TM) Jelly 2%; Shipments to Commence May 2012

TORONTO, ONTARIO--(Marketwire -05/09/12)- BioSyent Inc. ("BioSyent") (TSX-V: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has launched Cathejell™ Jelly 2% a Sterile Topical Anesthetic for the Canadian healthcare market.

Cathejell™ Jelly 2% is an innovative pharmaceutical product that combines a sterile gel and lidocaine in a unique collapsible applicator syringe which provides a safe and effective solution for patients to ease the discomfort of a range of medical procedures. Cathejell™ Jelly 2% is indicated for surface anesthesia and lubrication for various procedures including: male and female cystoscopies, catheterizations and other endourethral operations; endoscopies, proctoscopies, rectoscopies; and tracheal intubations. Cathejell™ Jelly 2% can also be used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Cathejell™ Jelly 2% was in-licensed by BioSyent Pharma from Pharmazeutische Fabrik MONTAVIT of Absam, Austria (MONTAVIT) and was approved by Health Canada in July 2011 (DIN 02370840). MONTAVIT has been producing and successfully marketing Cathejell™ Jelly 2% for over 40 years. Cathejell™ Jelly 2% is used by healthcare professionals in hospitals and clinics in over 50 countries around the world including England, Germany, France, Switzerland, Sweden, Italy and Spain.

Cathejell™ Jelly 2% has a unique collapsible syringe design with a trauma-free applicator tip that makes it easy to use for healthcare professionals and makes the application of the drug more comfortable for the subject patient.

Cathejell™ Jelly 2% is now available to all hospitals, pharmacies and urology clincs across Canada. Shipments for Cathejell™ Jelly 2% will commence in May 2012. For more information regarding Cathejell™ Jelly 2% visit www.cathejell.ca.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contact:

BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com